Extraosseous plasmacytoma in the nasal cavity after rituximab therapy against pulmonary MALT lymphoma

Ann Hematol. 2016 Oct;95(10):1733-5. doi: 10.1007/s00277-016-2751-6. Epub 2016 Jul 20.

Authors

Fumi Nakamura¹, Fumihiko Nakamura¹, Masako Ikemura², Masashi Fukayama², Mineo Kurokawa³

Affiliations

¹ Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
² Department of Pathology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
³ Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. [email protected].

PMID: 27435814
DOI: 10.1007/s00277-016-2751-6

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Clone Cells / pathology
Disease Progression
Female
Humans
Lung Diseases, Interstitial / complications
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Lymphoma, B-Cell, Marginal Zone / drug therapy*
Lymphoma, B-Cell, Marginal Zone / pathology
Nasal Cavity / pathology*
Neoplasms, Second Primary / pathology*
Neoplasms, Second Primary / radiotherapy
Nose Neoplasms / pathology*
Nose Neoplasms / radiotherapy
Plasmacytoma / pathology*
Plasmacytoma / radiotherapy
Rituximab / adverse effects
Rituximab / therapeutic use*
Sjogren's Syndrome / complications

Substances

Antineoplastic Agents
Rituximab